5. The most-studied therapeutic effect of ibogaine is the
reduction or elimination of addiction to opioids. An
integral effect is the alleviation of symptoms of opioid
withdrawal. Research also suggests that ibogaine may
be useful in treating dependence on other substances
such as alcohol, methamphetamine, and nicotine and
may affect compulsive behavioral patterns not involving
substance abuse or chemical dependence.
Researchers note that there remains a "need for
systematic investigation in a conventional clinical
research setting."[13]
^ a b c K.R. Alper, H.S. Lotsof, G.M. Frenken , D.J. Luciano , J. Bastiaans (1999). "Treatment of Acute Opioid Withdrawal with
Ibogaine". The American Journal on Addictions 8 (3): 234–42. doi:10.1080/105504999305848. PMID 10506904. Retrieved 2009-06-
16.
6. MAPS helps scientists design, fund, and obtain regulatory approval for
studies of the safety and effectiveness of a number of currently controlled
substances. MAPS works closely with government regulatory authorities
worldwide such as the United States Food and Drug Administration (FDA)
and the European Medicines Agency (EMEA) to ensure that all of its
sponsored research protocols conform to ethical and procedural guidelines
for clinical drug research.
7. MAPS is currently studying the long-term effects of
ibogaine treatment on patients presently undergoing
therapy at independent ibogaine treatment centers in
Mexico and New Zealand.
http://www.maps.org/research/ibogaine/
MAPS is collecting observational data for the first prospective ibogaine outcome
studies in order to contribute to the growing scientific literature about ibogaine as a
treatment for drug addiction.
8. It is proposed that intensive counseling, therapy and aftercare
during the interruption period following treatment is of significant
value. Some individuals require a second or third treatment
session with ibogaine over the course of the next 12 to 18 months.
A minority of individuals relapse completely into opiate addiction
within days or weeks. A comprehensive article (Lotsof 1995) on
the subject of ibogaine therapy detailing the procedure, effects
and aftereffects is found in "Ibogaine in the Treatment of Chemical
Dependence Disorders: Clinical Perspectives".[14] Ibogaine has
also been reported in multiple small-study cohorts to reduce
cravings for methamphetamine.[15]
11. Documentary films about ibogaine therapy
Detox or Die (2004) Directed by David Graham Scott.[50] David Graham Scott begins
videotaping his heroin-addicted friends. Before long, he himself is addicted to the
drug. He eventually turns the camera to himself and his family. After 12 years of
debilitating, painful dependence on methadone, Scott turns to ibogaine. Filmed in
Scotland and England, and broadcast on BBC One as the third installment in the
documentary series
One Life.[51] Ibogaine: Rite of Passage (2004) Directed by Ben Deloenen.[52] A heroin
addict undergoes ibogaine treatment at the Ibogaine Association, a clinic in Mexico.
Deloenen interviews people formerly addicted to heroin, cocaine, and
methamphetamine, who share their perspectives about ibogaine treatment. In
Gabon, a Babongo woman receives iboga root for her depressive malaise. Deloenen
visually contrasts this Western, clinical use of ibogaine with the Bwiti use of iboga
root, but emphasizes the Western context.
Facing the Habit (2007) Directed by Magnolia Martin.[53] Martin's subject is a former
millionaire and stockbroker who travels to Mexico for ibogaine treatment for heroin
addiction.
I'm Dangerous with Love (2009) Directed by Michel Negroponte.[54] Negroponte
examines Dimitri Mugianis's long, clandestine career of treating heroin addicts with
ibogaine.
12. ^ a b Keegan Hamilton (2010-11-17). "Ibogaine: Can it Cure Addiction Without the Hallucinogenic Trip?". Village Voice.
^ Kenneth Robert Alper (2001). "Chapter 1. Ibogaine: A review". 56. Academic Press. Retrieved 2012-09-10.
^ US patent 2813873, Morrice-Marie Janot & Robert Goutarel, "Derivatives of the ibogaine alkaloids", issued 1957-11-19, assigned to Les
Laboratoires Gobey
^ a b K.R. Alper, H.S. Lotsof, C.D. Kaplan (2008). "The Ibogaine Medical Subculture". J. Ethnopharmacology 115 (1): 9–24.
doi:10.1016/j.jep.2007.08.034. PMID 18029124. Retrieved 2008-02-22.
^ Berger ML, Palangsuntikul R, Rebernik P, Wolschann P, Berner H.. Screening of 64 Tryptamines at NMDA, 5-HT1A, and 5-HT2A Receptors: A
Comparative Binding and Modeling Study. 19. Current Medicinal Chemistry. PMID 22519402.
^ Glick, S. D.; Maisonneuve, I. M. (1998). "Mechanisms of Antiaddictive Actions of Ibogainea". Annals of the New York Academy of Sciences 844: 214–
226. doi:10.1111/j.1749-6632.1998.tb08237.x. PMID 9668680. edit
^ Wei, D.; Maisonneuve, I. M.; Kuehne, M. E.; Glick, S. D. (1998). "Acute iboga alkaloid effects on extracellular serotonin (5-HT) levels in nucleus
accumbens and striatum in rats". Brain Research 800 (2): 260–268. doi:10.1016/S0006-8993(98)00527-7. PMID 9685673. edit
^ a b c Samuel Obembe (06 August 2012). Practical Skills and Clinical Management of Alcoholism & Drug Addiction. Elsevier. p. 88.
ISBN 9780123985187.
^ GERSHOX, S.; LANG, J. (1962) (PDF). A PSYCHO-PHARMACOLOGICAL STUDY OF SOME INDOLE ALKALOIDS. Arch Int Pharmacodyn. Retrieved 2008-
05-27.
^ Maas U, Strubelt S (2006). "Fatalities after taking ibogaine in addiction treatment could be related to sudden cardiac death caused by autonomic
dysfunction". Med. Hypotheses 67 (4): 960–4. doi:10.1016/j.mehy.2006.02.050. PMID 16698188.
^ Hoelen DW, Spiering W, Valk GD (January 2009). "Long-QT syndrome induced by the antiaddiction drug ibogaine". N. Engl. J. Med. 360 (3): 308–9.
doi:10.1056/NEJMc0804248. PMID 19144953.
^ "Grapefruit juice: Beware of dangerous medication interactions". Retrieved 2010-09-10.
^ a b c K.R. Alper, H.S. Lotsof, G.M. Frenken , D.J. Luciano , J. Bastiaans (1999). "Treatment of Acute Opioid Withdrawal with Ibogaine". The American
Journal on Addictions 8 (3): 234–42. doi:10.1080/105504999305848. PMID 10506904. Retrieved 2009-06-16.
^ Lotsof, H.S. (1995). Ibogaine in the Treatment of Chemical Dependence Disorders: Clinical Perspectives. 3. MAPS Bulletin. pp. 19–26.
^ Giannini, A. James (1997). Drugs of Abuse (2 ed.). Practice Management Information Corporation. ISBN 1-57066-053-0.
^ A. Ludwig, J. Levine, L. Stark, R. Lazar (1969). A Clinical Study of LSD Treatment in Alcoholism. The American Journal of Psychiatry.
^ US patent 2817623, Jurg Schneider, "Tabernanthine, Ibogaine Containing Analgesic Compositions.", issued 1957-12-24, assigned to Ciba
Pharmaceuticals Inc.
^ Patrick K. Kroupa, Hattie Wells (2005) (PDF). Ibogaine in the 21st Century. XV. Multidisciplinary Association for Psychedelic Studies.. pp. 21–25.
^ Naranjo, Claudio (1973). "V, Ibogaine: Fantasy and Reality". The healing journey: new approaches to consciousness. New York: Pantheon Books.
pp. 197–231. ISBN 0-394-48826-1. Retrieved 2012-08-15.
^ J. Dybowski, E. Landrin (1901). "PLANT CHEMISTRY. Concerning Iboga, its excitement-producing properties, its composition, and the new alkaloid it
contains, ibogaine". C. R. Acad. Sci. 133: 748.
^ G. Büchi, D.L. Coffen, Karoly Kocsis, P.E. Sonnet, and Frederick E. Ziegler (1966). "The Total Synthesis of Iboga Alkaloids" (PDF). J. Am. Chem. Soc. 88
(13): 3099–3109. doi:10.1021/ja00965a039.
^ Frauenfelder, Christine (1999). Doctoral Thesis (Thesis). p. 24. Archived from the original on 2012-08-17.
^ ^ "Echoes" at the Internet Movie Database
13. Dzoljic ED, Kaplan CD, Dzoljic MR (1988). "Effect of ibogaine on naloxone-precipitated withdrawal syndrome in chronic morphine-dependent
rats". Arch Int Pharmacodyn Ther 294: 64–70. PMID 3233054.
^ Glick SD, Rossman K, Steindorf S, Maisonneuve IM, Carlson JN (1991). "Effects and aftereffects of ibogaine on morphine self-administration
in rats". Eur. J. Pharmacol 195 (3): 341–345. doi:10.1016/0014-2999(91)90474-5. PMID 1868880.
^ Cappendijk SLT, Dzoljic MR (1993). "Inhibitory effects of ibogaine on cocaine self-administration in rats". European Journal of Pharmacology
241 (2–3): 261–265. doi:10.1016/0014-2999(93)90212-Z. PMID 8243561.
^ Rezvani A, Overstreet D, Lee Y (1995). "Attenuation of alcohol intake by ibogaine in three strains of alcohol preferring rats". Pharmacology,
Biochemistry, and Behaviour 52 (3): 615–20. doi:10.1016/0091-3057(95)00152-M. PMID 8545483.
^ Kenneth R. Alper, Dana Beal and Charles D. Kaplan. A Contemporary History of Ibogaine in the United States and Europe. "IBOGAINE:
PROCEEDINGS OF THE FIRST INTERNATIONAL CONFERENCE". THE ALKALOIDS 56. Retrieved 2012-08-15.
^ Taylor WI (1965). "The Iboga and Voacanga Alkaloids". The Alkaloids: Chemistry and Physiology. pp. 203, 207–208.
^ a b Kontrimaviciūte V, Mathieu O, Mathieu-Daudé JC et al. (September 2006). "Distribution of ibogaine and noribogaine in a man following a
poisoning involving root bark of the Tabernanthe iboga shrub". J Anal Toxicol 30 (7): 434–40. PMID 16959135.
^ Rick Doblin (ppt). A Non-Profit Approach to Developing Ibogaine into an FDA-Approved Medication. Retrieved 2012-08-16.
^ Alper KR, Lotsof HS, Frenken GM, Luciano DJ, Bastiaans J (1999). "Treatment of acute opioid withdrawal with ibogaine" (PDF). Am J Addict
8 (3): 234–42. doi:10.1080/105504999305848. PMID 10506904.
^ Mash DC, Kovera CA, Pablo J et al. (September 2000). "Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy
measures". Ann. N. Y. Acad. Sci. 914: 394–401. doi:10.1111/j.1749-6632.2000.tb05213.x. PMID 11085338.
^ Jenks, C. (2002). "Extraction Studies ofTabernanthe IbogaandVoacanga Africana". Natural Product Letters 16 (1): 71–76.
doi:10.1080/1057563029001/4881. PMID 11942686. edit
^ Shulgin, Alexander; Shulgin, Ann (1997). TiHKAL. p. 487.
^ Pace CJ, Glick SD, Maisonneuve IM et al. (May 2004). "Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-
administration". Eur. J. Pharmacol. 492 (2–3): 159–67. doi:10.1016/j.ejphar.2004.03.062. PMID 15178360.
^ Glick SD, Kuehne ME, Raucci J et al. (September 1994). "Effects of iboga alkaloids on morphine and cocaine self-administration in rats:
relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum". Brain Res. 657 (1–2): 14–22.
doi:10.1016/0006-8993(94)90948-2. PMID 7820611.
^ Tsing Hua. (2006-01-28). Antiaddictive indole alkaloids in Ervatamia yunnanensis and their bioactivity. Academic Journal of Second Military
Medical University. Retrieved 2012-08-15.
^ P. Popik, P. Skolnick (1998). Pharmacology of Ibogaine and Ibogaine-Related Alkaloids. The Alkaloids 52, Chapter 3, 197-231, Academic
Press, Editor: G.A. Cordell
^ Kenneth R. Alper; Glick, Stanley D. (2001). "Ibogaine: A Review" (PDF). The alkaloids: chemistry and biology. 56. San Diego: Academic.
pp. 1–38. ISBN 0-12-469556-6.
^ Xu Z, Chang LW, Slikker W, Ali SF, Rountree RL, Scallet AC (September 2000). "A dose-response study of ibogaine-induced neuropathology
in the rat cerebellum". Toxicol. Sci. 57 (1): 95–101. doi:10.1093/toxsci/57.1.95. PMID 10966515.
^ Maciulaitis R, Kontrimaviciute V, Bressolle FM, Briedis V (March 2008). "Ibogaine, an anti-addictive drug: pharmacology and time to go
further in development. A narrative review". Hum Exp Toxicol 27 (3): 181–94. doi:10.1177/0960327107087802. PMID 18650249.
^ Baumann MH, Rothman RB, Pablo JP, Mash DC (1 May 2001). "In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite,
12-hydroxyibogamine (noribogaine), in rats". J. Pharmacol. Exp. Ther. 297 (2): 531–9. PMID 11303040.
14. ^ Hough LB, Bagal AA, Glick SD (March 2000). "Pharmacokinetic characterization of the indole alkaloid
ibogaine in rats". Methods Find Exp Clin Pharmacol 22 (2): 77–81. doi:10.1358/mf.2000.22.2.796066.
PMID 10849889.
^ Zubaran C, Shoaib M, Stolerman IP, Pablo J, Mash DC (July 1999). "Noribogaine generalization to the
ibogaine stimulus: correlation with noribogaine concentration in rat brain". Neuropsychopharmacology 21 (1):
119–26. doi:10.1016/S0893-133X(99)00003-2. PMID 10379526.
^ Scheduling Actions Controlled Substances Regulated Chemicals. Retrieved 2012-08-23.
^ Johnson, Gail (2003-01-02). "Ibogaine: A one-way trip to sobriety, pot head says". straight.com. Retrieved
2009-11-05.
^ . Canadian Department of Justice. 1996. http://laws.justice.gc.ca/en/C-38.8/. Retrieved 2009-11-05.
^ "Iboga Foundation". Iboga Foundation. 2011-11-26. Retrieved 2012-08-14.
^ "Iboga Foundation". Iboga Foundation. 2011-09-23. Retrieved 2012-08-14.
^ Detox or Die (2004) at the Internet Movie Database
^ One Life at the British Film Institute
^ Ibogaine: Rite of Passage (2004) at the Internet Movie Database
^ Facing the Habit (2007) at the Internet Movie Database
^ Dangerous with Love (2009) at the Internet Movie Database
^ Fear and Loathing on the Campaign Trail '72. Straight Arrow Books. 1973. pp. 150–154. ISBN 978-0-87932-
053-9.
^ "National Geogrpahic's 'Drugs, Inc.' on Hallucinogens: LSD, Mushrooms, Ayahuasca & Ibogaine".
CelebStoner.com. 2012-01-17. Retrieved 2012-08-14.
^ "Via Negativa" at the Internet Movie Database
^ "Getting Off" at the Internet Movie Database
^ "Users" at the Internet Movie Database
